- Home
- TYRA vs PHAR Comparison
TYRA vs PHAR Comparison
Compare TYRA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- PHAR
- Stock Information
- Founded
- TYRA 2018
- PHAR 1988
- Country
- TYRA United States
- PHAR Netherlands
- Employees
- TYRA N/A
- PHAR N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- TYRA Health Care
- PHAR Health Care
- Exchange
- TYRA Nasdaq
- PHAR Nasdaq
- Market Cap
- TYRA 819.3M
- PHAR 679.0M
- IPO Year
- TYRA 2021
- PHAR N/A
- Fundamental
- Price
- TYRA $15.91
- PHAR $9.55
- Analyst Decision
- TYRA Strong Buy
- PHAR Strong Buy
- Analyst Count
- TYRA 6
- PHAR 3
- Target Price
- TYRA $30.50
- PHAR $27.00
- AVG Volume (30 Days)
- TYRA 261.4K
- PHAR 5.4K
- Earning Date
- TYRA 03-18-2025
- PHAR 03-13-2025
- Dividend Yield
- TYRA N/A
- PHAR N/A
- EPS Growth
- TYRA N/A
- PHAR N/A
- EPS
- TYRA N/A
- PHAR N/A
- Revenue
- TYRA N/A
- PHAR $285,745,000.00
- Revenue This Year
- TYRA N/A
- PHAR $20.08
- Revenue Next Year
- TYRA N/A
- PHAR $9.22
- P/E Ratio
- TYRA N/A
- PHAR N/A
- Revenue Growth
- TYRA N/A
- PHAR 30.64
- 52 Week Low
- TYRA $12.34
- PHAR $6.65
- 52 Week High
- TYRA $29.60
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- TYRA 52.83
- PHAR 50.97
- Support Level
- TYRA $15.75
- PHAR $9.37
- Resistance Level
- TYRA $17.27
- PHAR $10.01
- Average True Range (ATR)
- TYRA 0.91
- PHAR 0.52
- MACD
- TYRA 0.20
- PHAR -0.10
- Stochastic Oscillator
- TYRA 65.99
- PHAR 28.08
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.